These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 6873137)
1. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. Nuotto E Eur J Clin Pharmacol; 1983; 24(5):603-9. PubMed ID: 6873137 [TBL] [Abstract][Full Text] [Related]
2. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study. Laitinen LA; Tokola O; Gothoni G; Vapaatalo H Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299 [TBL] [Abstract][Full Text] [Related]
3. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations. Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260 [TBL] [Abstract][Full Text] [Related]
4. Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects. Parrott AC; Wesnes K Psychopharmacology (Berl); 1987; 92(4):513-9. PubMed ID: 3114803 [TBL] [Abstract][Full Text] [Related]
5. Effects of scopolamine and dextroamphetamine on human performance. Schmedtje JF; Oman CM; Letz R; Baker EL Aviat Space Environ Med; 1988 May; 59(5):407-10. PubMed ID: 3390096 [TBL] [Abstract][Full Text] [Related]
6. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Curran HV; Schifano F; Lader M Psychopharmacology (Berl); 1991; 103(1):83-90. PubMed ID: 2006245 [TBL] [Abstract][Full Text] [Related]
7. The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance. Parrott AC Psychopharmacology (Berl); 1986; 89(3):347-54. PubMed ID: 3088662 [TBL] [Abstract][Full Text] [Related]
8. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function. Golding JF; Wesnes KA; Leaker BR Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648 [TBL] [Abstract][Full Text] [Related]
9. Psychophysiological measurements after oral atropine in man. Seppälä T; Visakorpi R Acta Pharmacol Toxicol (Copenh); 1983 Jan; 52(1):68-74. PubMed ID: 6837325 [TBL] [Abstract][Full Text] [Related]
10. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Nachum Z; Shupak A; Gordon CR Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539 [TBL] [Abstract][Full Text] [Related]
12. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Duka T; Ott H; Rohloff A; Voet B Psychopharmacology (Berl); 1996 Feb; 123(4):361-73. PubMed ID: 8867876 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of antimotion sickness drug side effects on performance. Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Golding JF; Stott JR Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Kennedy RS; Odenheimer RC; Baltzley DR; Dunlap WP; Wood CD Aviat Space Environ Med; 1990 Jul; 61(7):615-21. PubMed ID: 2386447 [TBL] [Abstract][Full Text] [Related]
18. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308 [TBL] [Abstract][Full Text] [Related]
19. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218 [TBL] [Abstract][Full Text] [Related]
20. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine. Graybiel A; Cramer DB; Wood CD Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]